✦ LIBER ✦

Mutational analysis and clinical correlation of metastatic colorectal cancer

✍ Scribed by Russo, Andrea L.; Borger, Darrell R.; Szymonifka, Jackie; Ryan, David P.; Wo, Jennifer Y.; Blaszkowsky, Lawrence S.; Kwak, Eunice L.; Allen, Jill N.; Wadlow, Raymond C.; Zhu, Andrew X.; Murphy, Janet E.; Faris, Jason E.; Dias-Santagata, Dora; Haigis, Kevin M.; Ellisen, Leif W.; Iafrate, Anthony J.; Hong, Theodore S.

Book ID: 124165868
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 192 KB
Volume: 120
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.28599

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

103 KRAS mutational spectra in routine d

103 KRAS mutational spectra in routine diagnostic analysis of metastatic colorectal cancer

✍ K. Jakovljevic; E. Malisic; J. Dobricic; M. Spasic; R. Jankovic 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

KRAS mutations in primary and metastatic

KRAS mutations in primary and metastatic colorectal cancer

✍ Cheng-Bo Han, Fan Li, Jie-Tao Ma… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 55 KB

KRAS mutation detection by high-resoluti

KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer

✍ Malapelle, U; Carlomagno, C; Salatiello, M; De Stefano, A; De Luca, C; Bianco, R 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 439 KB

KRAS mutational status assessment in pat

KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?

✍ M. HEBBAR; P. FOURNIER; O. ROMANO 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Association of K-ras Mutational Status a

Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone

✍ Daniel J. Freeman; Todd Juan; Maureen Reiner; J. Randolph Hecht; Neal J. Meropol 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 502 KB

Association of K-ras Mutational Status a

Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone

✍ Daniel J. Freeman; Todd Juan; Maureen Reiner; J. Randolph Hecht; Neal J. Meropol 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 502 KB

Background: Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K-ras, BRAF, and PIK3CA gene mutations with tumor resistance to panitumumab alone. Patients and Methods: From 3 phase II panitumumab metastatic colorectal cancer (mCRC)